NM_000141.5(FGFR2):c.1013G>A (p.Gly338Glu) AND FGFR2-related craniosynostosis

Germline classification:: Pathogenic (1 submission)
Last evaluated:: Oct 29, 2023
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV001377881.6

Allele description [Variation Report for NM_000141.5(FGFR2):c.1013G>A (p.Gly338Glu)]

NM_000141.5(FGFR2):c.1013G>A (p.Gly338Glu)

Gene:

FGFR2:fibroblast growth factor receptor 2 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

10q26.13

Genomic location:

Preferred name:

NM_000141.5(FGFR2):c.1013G>A (p.Gly338Glu)

HGVS:

NC_000010.11:g.121517390C>T
NG_012449.2:g.86069G>A
NM_000141.5:c.1013G>AMANE SELECT
NM_001144913.1:c.1087+1292G>A
NM_001144914.1:c.749-2071G>A
NM_001144915.2:c.746G>A
NM_001144916.2:c.668G>A
NM_001144917.2:c.939+2589G>A
NM_001144918.2:c.668G>A
NM_001144919.2:c.820+1292G>A
NM_001320654.2:c.329G>A
NM_001320658.2:c.1013G>A
NM_022970.4:c.1087+1292G>A
NM_023029.2:c.746G>A
NP_000132.3:p.Gly338Glu
NP_000132.3:p.Gly338Glu
NP_001138387.1:p.Gly249Glu
NP_001138388.1:p.Gly223Glu
NP_001138390.1:p.Gly223Glu
NP_001307583.1:p.Gly110Glu
NP_001307587.1:p.Gly338Glu
NP_075418.1:p.Gly249Glu
LRG_994t1:c.1013G>A
LRG_994:g.86069G>A
LRG_994p1:p.Gly338Glu
NC_000010.10:g.123276904C>T
NM_000141.4:c.1013G>A
NR_073009.2:n.1449G>A
p.[Gly338Glu]

Protein change:

G110E

Links:

dbSNP: rs1057519044

NCBI 1000 Genomes Browser:

rs1057519044

Molecular consequence:

NM_001144913.1:c.1087+1292G>A - intron variant - [Sequence Ontology: SO:0001627]
NM_001144914.1:c.749-2071G>A - intron variant - [Sequence Ontology: SO:0001627]
NM_001144917.2:c.939+2589G>A - intron variant - [Sequence Ontology: SO:0001627]
NM_001144919.2:c.820+1292G>A - intron variant - [Sequence Ontology: SO:0001627]
NM_022970.4:c.1087+1292G>A - intron variant - [Sequence Ontology: SO:0001627]
NM_000141.5:c.1013G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001144915.2:c.746G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001144916.2:c.668G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001144918.2:c.668G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001320654.2:c.329G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001320658.2:c.1013G>A - missense variant - [Sequence Ontology: SO:0001583]
NM_023029.2:c.746G>A - missense variant - [Sequence Ontology: SO:0001583]
NR_073009.2:n.1449G>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:: FGFR2-related craniosynostosis
Identifiers:: MedGen: CN231480

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV001575328	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Pathogenic (Oct 29, 2023)	germline	clinical testing	PubMed (4) [See all records that cite these PMIDs] 8946174, 11870239, 24127277, 28492532

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV001575328

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Pathogenic
(Oct 29, 2023)

germline

clinical testing

PubMed (4)
[See all records that cite these PMIDs]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Spectrum of craniosynostosis phenotypes associated with novel mutations at the fibroblast growth factor receptor 2 locus.

Pulleyn LJ, Reardon W, Wilkes D, Rutland P, Jones BM, Hayward R, Hall CM, Brueton L, Chun N, Lammer E, Malcolm S, Winter RM.

Eur J Hum Genet. 1996;4(5):283-91.

PubMed [citation]

PMID:: 8946174

Pregnancy following preimplantation genetic diagnosis for Crouzon syndrome.

Abou-Sleiman PM, Apessos A, Harper JC, Serhal P, Delhanty JD.

Mol Hum Reprod. 2002 Mar;8(3):304-9.

PubMed [citation]

PMID:: 11870239

See all PubMed Citations (4)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001575328.4

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (4)

Description

This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 338 of the FGFR2 protein (p.Gly338Glu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of Crouzon syndrome (PMID: 8946174, 11870239, 24127277; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 374817). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FGFR2 protein function with a positive predictive value of 95%. This variant disrupts the p.Gly338 amino acid residue in FGFR2. Other variant(s) that disrupt this residue have been determined to be pathogenic (Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine